Search results
28 gru 2022 · Myelofibrosis is considered to be a chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders. Myelofibrosis can happen on its own (primary myelofibrosis) or it can develop from another bone marrow disorder (secondary myelofibrosis).
16 cze 2023 · Advances in treatment have improved the prognosis of people with chronic myelogenous leukemia. Most people can achieve remission and live for many years after diagnosis. Chronic myelogenous leukemia often doesn't cause symptoms. It might be detected during a blood test. When they occur, symptoms may include: Bone pain. Bleeding easily.
26 lut 2019 · Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P <.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post-1990) (P <.001), whereas survival data were time independent in PV and PMF.
28 gru 2022 · Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition. Coping and support. Living with myelofibrosis may involve coping with pain, discomfort, uncertainty and the side effects of long-term treatments.
25 mar 2024 · Life expectancy for myelofibrosis varies based on age, blood cell counts, and symptoms. Some experience rapid progression, while others may live longer without symptoms.
19 gru 2023 · What is the prognosis for myelofibrosis? The outlook for someone with myelofibrosis depends on factors such as age, blood cell counts, and symptoms. For some people, the condition progresses more...
To describe the long-term natural history of essential thrombocythemia (ET) in terms of life expectancy, risk of disease transformation into a more aggressive myeloid disorder, and prognostic factors for both survival and disease complications.
